C2CD4C

Across TCGA pan-cancer cohorts, C2CD4C mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C2CD4C data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher C2CD4C mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C2CD4C expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC and GBM are the cancer types where C2CD4C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.822	1.000	.004	18	view →
GBM	OS	Quartile	All	0.920	0.728	.011	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

C2CD4C–CCRCC (DFS)

Open the CCRCC breakdown →